Dec 8, 2025 08:36AM Autolus presents pediatric data for obe-cel at ASH meeting

Aug 12, 2025 07:24AM Autolus Therapeutics (AUTL) Tops Q2 EPS by 5c

Jul 21, 2025 07:01AM Autolus receives European approval for CAR T therapy AUCATZYL

Jun 27, 2025 11:31AM FDA removing REMS from several CAR-T cell therapies positive for these 3 stocks - William Blair

May 23, 2025 08:31AM Autolus Therapeutics (AUTL) Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with R/R B-ALL

May 8, 2025 07:21AM Autolus Therapeutics (AUTL) Reports In-Line Q1 EPS

Apr 25, 2025 12:07PM Autolus Therapeutics (AUTL) Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblast

Mar 31, 2025 10:16AM Autolus Therapeutics plc (AUTL) PT Lowered to $10 at Truist Securities

Mar 24, 2025 08:05AM Agilent Technologies (A) xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

Mar 20, 2025 12:39PM Mizuho Reiterates Outperform Rating on Autolus Therapeutics plc (AUTL), PT $12

Mar 20, 2025 12:35PM Truist Defending Autolus Therapeutics plc (AUTL), PT $11, 'Our analysis of Aucatzyl ATCs indicate a good deployment strategy'

Jan 17, 2025 07:00AM Autolus Therapeutics (AUTL) Presents Clinical Data Updates at the 2025 Tandem Meetings

Dec 2, 2024 07:04AM Autolus Therapeutics (AUTL) Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

Nov 15, 2024 02:43AM Redburn-Atlantic Upgrades Autolus Therapeutics plc (AUTL) to Buy

Nov 12, 2024 04:21PM Autolus Therapeutics (AUTL) Misses Q3 EPS by 10c

Sep 19, 2024 07:03AM Autolus Therapeutics (AUTL) Appoints Matthias Will as Chief Development Officer

Aug 27, 2024 07:00AM Autolus Therapeutics (AUTL) Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

Aug 8, 2024 07:20AM Autolus Therapeutics (AUTL) Misses Q2 EPS by 3c